Precigen (PGEN) Stock Price
Precigen Price
Over the last 14 years Precigen grew revenue by 1.4% annually, reaching 9.68 M USD. For Precigen, the net margin of -2,588.2% is down versus -646.0% a few years ago. The consensus 12-month price target for Precigen is 8.67 USD, about 22.1% above where the stock trades today. Of 9 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 129% above its 52-week low.
Precigen stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Precigen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Precigen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Precigen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Precigen Price |
|---|---|
| 9/4/2026 | 7.10 USD |
| 9/3/2026 | 7.14 USD |
| 9/2/2026 | 7.01 USD |
| 9/1/2026 | 6.86 USD |
| 8/31/2026 | 6.93 USD |
| 8/30/2026 | 6.85 USD |
| 8/28/2026 | 6.97 USD |
| 8/27/2026 | 7.39 USD |
| 8/26/2026 | 7.42 USD |
| 8/25/2026 | 7.28 USD |
| 8/24/2026 | 7.09 USD |
| 8/21/2026 | 7.20 USD |
| 8/20/2026 | 7.44 USD |
| 8/19/2026 | 7.03 USD |
| 8/18/2026 | 6.49 USD |
| 8/14/2026 | 6.10 USD |
| 8/13/2026 | 6.49 USD |
| 8/12/2026 | 6.82 USD |
| 8/10/2026 | 7.14 USD |
| 8/7/2026 | 7.23 USD |
| 8/6/2026 | 6.91 USD |
| 8/5/2026 | 6.84 USD |
| 8/4/2026 | 6.66 USD |
| 8/3/2026 | 6.61 USD |
| 7/31/2026 | 6.27 USD |
| 7/30/2026 | 5.94 USD |
| 7/29/2026 | 5.47 USD |
| 7/27/2026 | 5.62 USD |
| 7/23/2026 | 5.54 USD |
| 7/22/2026 | 5.32 USD |
Precigen Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Precigen Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 173.00 | 190.00 | 230.00 | 160.00 | 31.00 | 31.00 | 14.00 | 26.00 | 6.00 | 3.00 | 9.00 | 232.00 | 454.00 | 444.00 | 687.00 | 878.00 |
| 143.66 | 9.83 | 21.05 | -30.43 | -80.63 | – | -54.84 | 85.71 | -76.92 | -50.00 | 200.00 | 2,477.78 | 95.69 | -2.20 | 54.73 | 27.80 |
| 63.01 | 67.89 | 73.04 | 60.62 | 83.87 | -38.71 | -278.57 | 76.92 | 50.00 | 100.00 | 33.33 | 33.33 | 33.33 | 33.33 | 33.33 | 33.33 |
| 109.00 | 129.00 | 168.00 | 97.00 | 26.00 | -12.00 | -39.00 | 20.00 | 3.00 | 3.00 | 3.00 | 77.33 | 151.33 | 148.00 | 229.00 | 292.67 |
| -146.00 | -125.00 | -137.00 | -505.00 | -86.00 | -86.00 | -91.00 | -73.00 | -99.00 | -135.00 | -246.00 | 57.00 | 272.00 | 247.00 | 457.00 | 596.00 |
| -84.39 | -65.79 | -59.57 | -315.63 | -277.42 | -277.42 | -650.00 | -280.77 | -1,650.00 | -4,500.00 | -2,733.33 | 24.57 | 59.91 | 55.63 | 66.52 | 67.88 |
| -84.00 | -186.00 | -117.00 | -509.00 | -170.00 | -170.00 | -92.00 | 28.00 | -95.00 | -126.00 | -250.00 | 49.00 | 241.00 | 217.00 | 403.00 | 527.00 |
| 3.70 | 121.43 | -37.10 | 335.04 | -66.60 | – | -45.88 | -130.43 | -439.29 | 32.63 | 98.41 | -119.60 | 391.84 | -9.96 | 85.71 | 30.77 |
| 116.47 | 118.58 | 120.76 | 131.53 | 155.23 | 178.23 | 199.26 | 208.15 | 248.92 | 292.87 | 312.98 | 312.98 | 312.98 | 312.98 | 312.98 | 312.98 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Precigen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Precigen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Precigen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Precigen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Precigen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Precigen stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Precigen Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Precigen business model & stock analysis
Precigen SWOT Analysis
Strengths
Precigen Inc. has a strong reputation and a well-established presence in the biotechnology industry. The company possesses advanced technological capabilities and a diverse portfolio of innovative products and services. Precigen Inc. has a team of highly skilled professionals who contribute to its success. Moreover, the company has a robust financial position, providing stability and the ability to invest in research and development.
Weaknesses
One of the weaknesses of Precigen Inc. is its dependency on few key customers. This creates a risk of revenue concentration and potential financial impact if any of these customers reduce or discontinue their business with the company. Additionally, Precigen Inc. may face challenges in scaling up its operations and managing growth, which can hinder its ability to effectively meet market demand.
Opportunities
The biotechnology industry is constantly evolving, presenting numerous opportunities for Precigen Inc. to expand its product offerings and diversify its revenue streams. The increasing demand for advanced genetic engineering and gene editing technologies opens up new avenues for the company. Precigen Inc. can also benefit from strategic collaborations and partnerships to leverage complementary expertise and gain access to new markets.
Threats
Precigen Inc. operates in a highly competitive industry, facing threats from both established players and emerging companies. Rapid technological advancements, regulatory changes, and intellectual property disputes pose risks to the company's market position and profitability. External factors, such as economic downturns or geopolitical uncertainties, can impact customer spending and overall demand for biotechnology products.
Precigen Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Precigen Segments
Precigen Revenue by Segment (1/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Precigen Revenue by Segment (2/5)
Max
Details
Precigen Revenue by Segment (3/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Precigen Revenue by Segment (4/5)
Max
Details
Precigen Revenue by Segment (5/5)
Max
Details
Precigen Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Precigen Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Precigen historical P/E ratio, EBIT multiple, and P/S ratio
Precigen annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Precigen shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Precigen forecasts and price targets in September 2026
Analyst Price Targets 2026Precigen Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/5/2026 | Maintained | Buy | – | |
| 8/3/2026 | Maintained | Buy | – | |
| 5/28/2026 | Maintained | Buy | – | |
| 5/14/2026 | Maintained | Buy | – | |
| 5/14/2026 | Maintained | Market Outperform | – | |
| 3/26/2026 | Maintained | Buy | – | |
| 3/26/2026 | Maintained | Market Outperform | – | |
| 11/14/2025 | Maintained | Buy | – | |
| 8/19/2025 | Maintained | Market Outperform | – | |
| 8/19/2025 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Precigen Earnings Calls
Precigen Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/10/2026 | -0.01USD | - | 28.39 MUSD | - | 2026 Q2 |
| 5/13/2026 | -0.03USD | - | 21.22 MUSD | - | 2026 Q1 |
| 3/25/2026 | -0.09USD | - | 8.45 MUSD | - | 2025 Q4 |
| 11/13/2025 | -0.10USD | - | 510,000.00USD | - | 2025 Q3 |
| 8/12/2025 | -0.08USD | - | 680,003.00USD | - | 2025 Q2 |
| 11/12/2024 | -0.08USD | - | 1.28 MUSD | - | 2024 Q3 |
| 5/8/2024 | -0.08USD | - | 1.02 MUSD | - | 2024 Q1 |
| 3/4/2024 | -0.08USD | - | 1.73 MUSD | - | 2023 Q4 |
| 11/7/2023 | -0.11USD | - | 6.32 MUSD | - | 2023 Q3 |
| 8/7/2023 | -0.11USD | - | 3.35 MUSD | - | 2023 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Precigen stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Precigen shareholder structure
| % | Name |
|---|---|
5.03572% | |
4.30252% | |
3.07787% | |
2.02052% | |
1.92239% | |
1.87789% |
Precigen Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
35.90% | SEC ↗ | |
26.10% | SEC ↗ | |
22.90% | SEC ↗ | |
14.70% | SEC ↗ | |
14.70% | SEC ↗ | |
13.50% | SEC ↗ | |
10.20% | SEC ↗ | |
9.20% | SEC ↗ | |
5.90% | SEC ↗ | |
5.80% | SEC ↗ |
Precigen Executives and Management Board
13 members · avg. age 64 · 23 % women
Dr. Helen Sabzevari (63)
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc. · since 2017
5.43 M USD
Management
Mr. Rutul Shah (44)
Chief Operating Officer
Mr. Harry Thomasian (63)
Chief Financial Officer
Mr. Donald Lehr (50)
Chief Legal Officer, Corporate Secretary
Mr. Phil Tennant (55)
Chief Commercial Officer
Board of Directors
Mr. Randal Kirk (71)
Executive Chairman of the Board · since 2008
Ms. Nancy Agee (72)
Independent Director
Mr. Jeffrey Kindler (69)
Independent Director
Mr. James Turley (69)
Lead Independent Director
Mr. Cesar Alvarez (77)
Independent Director
Ms. Vinita Gupta (57)
Independent Director
Frequently asked questions about Precigen
Precigen Inc is a biotechnology company focused on utilizing its proprietary synthetic biology technology to develop innovative solutions to global challenges. The business model of Precigen revolves around leveraging its expertise in gene and cell therapy, as well as its advanced bioinformatics capabilities, to address critical needs in healthcare, agriculture, and environmental conservation. With a strong emphasis on precision medicine, the company aims to develop personalized therapies and genetic engineering solutions. Precigen Inc collaborates with various partners to accelerate the development and commercialization of its products and services, aiming to make a positive impact on society through cutting-edge biotechnology advancements.
Precigen Inc is primarily active in the biotechnology industry. As a leading biotech company, Precigen focuses on developing advanced gene and cell therapies, genetic medicines, and agricultural biotechnology solutions. The company harnesses the power of innovative gene editing platforms to address significant unmet needs in healthcare and food production sectors. Precigen Inc leverages its cutting-edge technologies and extensive expertise to create transformative solutions for various genetic disorders, chronic diseases, and sustainable agriculture practices. With its commitment to innovation and scientific progress, Precigen Inc continues to play a vital role in shaping the biotechnology landscape.
The main competitors of Precigen Inc in the market include companies like Intrexon Corporation, Editas Medicine, CRISPR Therapeutics, and Sangamo Therapeutics.
Precigen Inc, formerly known as Intrexon Corporation, is a biotechnology company based in Germantown, Maryland. Established in 1998, Precigen focuses on applying synthetic biology to solve complex problems across various industries. The company is driven by a mission to create biologically-based solutions to improve the quality of life and promote sustainability. Precigen has expertise in the development and commercialization of advanced gene and cellular therapies, as well as agricultural biotech solutions. With its innovative approach and cutting-edge technologies, Precigen has established itself as a leader in the field of synthetic biology, continuously striving to push boundaries and make a positive impact on the world.
Precigen Inc, formerly known as Intrexon Corporation, has achieved several noteworthy milestones throughout its history. The company, a leader in synthetic biology, has successfully developed and commercialized various advanced technologies and solutions. Precigen Inc has made significant breakthroughs in the areas of gene and cell therapy, as well as synthetic gene technologies. These accomplishments include the successful clinical trials of their CAR-T therapy candidates, the development of their UltraVector® platform, and the creation of novel genetically modified organisms. Precigen Inc's continuous dedication to innovation and cutting-edge science has positioned them as one of the prominent players in the field.
Precigen Inc is primarily present in the United States and has its headquarters in Germantown, Maryland.
Precigen Inc represents a strong commitment to innovation, integrity, and social responsibility. As a leading biotechnology company, Precigen pioneers advancements in the field of genetic research. With a dedicated focus on developing therapies and solutions for human health, they prioritize scientific excellence and cutting-edge technology. Led by a team of experts, Precigen emphasizes collaboration and strategic partnerships to achieve their mission of transforming lives through innovative healthcare solutions. Through their dedication to improving global health outcomes and their unwavering dedication to their core values, Precigen Inc stands as a trusted name in the biotech industry.
Analysts currently set an average price target of 8.67 USD for the Precigen stock (median: 8.67 USD), implying +22.1 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Precigen stock: 7 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Precigen to generate revenue of 232.88 M USD and earnings per share of 0.16 USD.
Converted at the current exchange rate, the Precigen share trades at 6.11 EUR (7.10 USD).
The Precigen share (PGEN) is listed on 5 stock exchanges, including: NASDAQ (PGEN), Frankfurt (I5X), München (I5X.MU), Düsseldorf (I5X.DU), SIX (Zürich) (I5X.SW).
Precigen Inc, founded in 2000, is a biotechnology company headquartered in Germantown, Maryland. The company specializes in the development and application of gene editing technologies used in the therapy of severe diseases and genetic disorders. Precigen's business model is based on four main areas: therapeutic product development, agricultural biotechnology, industrial biotechnology, and research and development of genomic technology. Precigen develops therapeutics aimed at curing or alleviating serious diseases such as cancer and genetic disorders using its proprietary gene editing technology platforms like UltraPrecise, ActoBiotics, and X-Press. The company also works in agricultural biotechnology to develop innovative solutions for improving agricultural yields and promoting sustainable farming. In industrial biotechnology, Precigen leverages its expertise to contribute to the development of renewable energy and biofuels. The company explores and develops new technologies in genomics for diagnostic, therapeutic, and disease prevention purposes. Precigen emphasizes the ethical and social aspects of genetic research. Additionally, the company offers products and services based on its technology platforms, such as UltraVector, a proprietary vector design tool that supports DNA construction and gene editing processes. Precigen also holds a license for obtaining plasmid DNA, which helps reduce costs in the production of therapeutics or biotherapeutics. Overall, Precigen has developed a wide range of technologies and applications to assist customers in overcoming complex challenges in various fields, with a focus on gene editing technology and its applications in therapy, agriculture, industrial biotechnology, and genomic research.
The expected revenue of Precigen is 232.88 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Precigen is 49.53 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Precigen is currently 44.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Precigen stock.
The price-to-sales ratio (P/S) of Precigen is currently 9.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Precigen stock.
The Eulerpool Quality Score for Precigen is 2/10.
The ISIN of Precigen is US74017N1054. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Precigen is A2PZG1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Precigen is PGEN. The ticker symbol is used to trade Precigen shares on the stock exchange.
Precigen paid dividends every year for the past 0 years.
Precigen is assigned to the 'Health' sector.
The dividends of Precigen are distributed in USD.
Precigen stock
Precigen Peer Group
Precigen Ticker
Precigen FIGI
All fundamentals and in-depth analysis of Precigen
Our stock analysis for Precigen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Precigen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.